Peucemycin

Last updated
Peucemycin
Peucemycin.svg
Identifiers
3D model (JSmol)
  • CC\C=C\C1=C2OC(CC(=O)OC/C(=C\C(\CC)=C\CC)/C=C/C(O)C2O)=CC1=O
Properties
C24H30O6
Molar mass 414.498 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).

Peucemycin is a polyketide produced by Streptomyces peucetius , a Gram-positive filamentous bacteria that also produces the anticancer compounds daunorubicin and doxorubicin. [1] This compound was elucidated from a cryptic biosynthetic gene cluster and is produced under temperature-specific conditions for bacterial growth (metabolite is present at 18 °C but not 28 °C). [2] Peucemycin has demonstrated bioactivity against growth of S. aureus , P. hauseri , and S. enterica and also is weakly active against cancer cell lines. [2] Peucemycin is biosynthesized through a Type 1 PKS system. [2]

Biosynthesis

Peucemycin is synthesized through a type 1 polyketide synthase with 8 proposed modules from 5 PKS-related genes (peuA-peuE). [2] The type 1 PKS pathway used for biosynthesis is shown in Figure 1. The first gene, peuA, encodes for an initiation module and two elongation modules. The structure of the ketosynthase enzyme in the initiation module has a mutation of a cysteine residue to a glutamine residue that allows for decarboxylation of the starting material without condensation. [3] The next gene, peuB, encodes for modules 3 and 4. Sequencing data of Module 4 indicates presence of a dehydratase enzyme, but amino acid mutations leave this enzyme inactivated, meaning a singular hydroxyl group at carbon 9 is generated. Module 5 is encoded by peuC, and an additional gene, peuI, is proposed to introduce the butyl malonyl-CoA in this module. Modules 6 and 7 are encoded by peuD and peuE respectively. The forming polyketide chain is hydroxylated with cytochrome P450 enzymes, peuH and peuG, and the terminal thioesterase domain in Module 7 catalyzes the product release and macrocycle formation to form peucemycin.

Figure 1. Biosynthesis of Peucemycin via Type 1 PKS system. Enzymes are shown in colored circles and butyl malonyl-CoA moeity introduced by peuI is highlighted in yellow. PeucemycinBiosynthesisFigure.png
Figure 1. Biosynthesis of Peucemycin via Type 1 PKS system. Enzymes are shown in colored circles and butyl malonyl-CoA moeity introduced by peuI is highlighted in yellow.

Related Research Articles

<span class="mw-page-title-main">Oxytetracycline</span> Antibiotic

Oxytetracycline is a broad-spectrum tetracycline antibiotic, the second of the group to be discovered.

<span class="mw-page-title-main">Neocarzinostatin</span> Chemical compound

Neocarzinostatin (NCS) is a macromolecular chromoprotein enediyne antitumor antibiotic secreted by Streptomyces macromomyceticus.

Polyketide synthases (PKSs) are a family of multi-domain enzymes or enzyme complexes that produce polyketides, a large class of secondary metabolites, in bacteria, fungi, plants, and a few animal lineages. The biosyntheses of polyketides share striking similarities with fatty acid biosynthesis.

<span class="mw-page-title-main">Biosynthesis of doxorubicin</span>

Doxorubicin (DXR) is a 14-hydroxylated version of daunorubicin, the immediate precursor of DXR in its biosynthetic pathway. Daunorubicin is more abundantly found as a natural product because it is produced by a number of different wild type strains of streptomyces. In contrast, only one known non-wild type species, streptomyces peucetius subspecies caesius ATCC 27952, was initially found to be capable of producing the more widely used doxorubicin. This strain was created by Arcamone et al. in 1969 by mutating a strain producing daunorubicin, but not DXR, at least in detectable quantities. Subsequently, Hutchinson's group showed that under special environmental conditions, or by the introduction of genetic modifications, other strains of streptomyces can produce doxorubicin. His group has also cloned many of the genes required for DXR production, although not all of them have been fully characterized. In 1996, Strohl's group discovered, isolated and characterized dox A, the gene encoding the enzyme that converts daunorubicin into DXR. By 1999, they produced recombinant Dox A, a Cytochrome P450 oxidase, and found that it catalyzes multiple steps in DXR biosynthesis, including steps leading to daunorubicin. This was significant because it became clear that all daunorubicin producing strains have the necessary genes to produce DXR, the much more therapeutically important of the two. Hutchinson's group went on to develop methods to improve the yield of DXR, from the fermentation process used in its commercial production, not only by introducing Dox A encoding plasmids, but also by introducing mutations to deactivate enzymes that shunt DXR precursors to less useful products, for example baumycin-like glycosides. Some triple mutants, that also over-expressed Dox A, were able to double the yield of DXR. This is of more than academic interest because at that time DXR cost about $1.37 million per kg and current production in 1999 was 225 kg per annum. More efficient production techniques have brought the price down to $1.1 million per kg for the non-liposomal formulation. Although DXR can be produced semi-synthetically from daunorubicin, the process involves electrophilic bromination and multiple steps and the yield is poor. Since daunorubicin is produced by fermentation, it would be ideal if the bacteria could complete DXR synthesis more effectively.

In enzymology, an erythronolide synthase is an enzyme that catalyzes the chemical reaction

Streptogramin A is a group of antibiotics within the larger family of antibiotics known as streptogramins. They are synthesized by the bacteria Streptomyces virginiae. The streptogramin family of antibiotics consists of two distinct groups: group A antibiotics contain a 23-membered unsaturated ring with lactone and peptide bonds while group B antibiotics are depsipeptides. While structurally different, these two groups of antibiotics act synergistically, providing greater antibiotic activity than the combined activity of the separate components. These antibiotics have until recently been commercially manufactured as feed additives in agriculture, although today there is increased interest in their ability to combat antibiotic-resistant bacteria, particularly vancomycin-resistant bacteria.

<span class="mw-page-title-main">Nogalamycin</span> Chemical compound

Nogalamycin is an anthracycline antibiotic produced by the soil bacteria Streptomyces nogalater. It has antitumor properties but it is also highly cardiotoxic. The less cardiotoxic semisynthetic analog menogaril was developed in the 1970s. Currently nogalamycin and menogaril are not used clinically.

<span class="mw-page-title-main">Pikromycin</span> Chemical compound

Pikromycin was studied by Brokmann and Hekel in 1951 and was the first antibiotic macrolide to be isolated. Pikromycin is synthesized through a type I polyketide synthase system in Streptomyces venezuelae, a species of Gram-positive bacterium in the genus Streptomyces. Pikromycin is derived from narbonolide, a 14-membered ring macrolide. Along with the narbonolide backbone, pikromycin includes a desosamine sugar and a hydroxyl group. Although Pikromycin is not a clinically useful antibiotic, it can be used as a raw material to synthesize antibiotic ketolide compounds such as ertythromycins and new epothilones.

Streptomyces peucetius is a bacterium species in the genus Streptomyces.

Curacin A is a hybrid polyketide synthase (PKS)/nonribosomal peptide synthase (NRPS) derived natural product produced isolated from the cyanobacterium Lyngbya majuscula. Curacin A belongs to a family of natural products including jamaicamide, mupirocin, and pederin that have an unusual terminal alkene. Additionally, Curacin A contains a notable thiazoline ring and a unique cyclopropyl moiety, which is essential to the compound's biological activity. Curacin A has been characterized as potent antiproliferative cytotoxic compound with notable anticancer activity for several cancer lines including renal, colon, and breast cancer. Curacin A has been shown to interact with colchicine binding sites on tubulin, which inhibits microtubule polymerization, an essential process for cell division and proliferation.

<span class="mw-page-title-main">Herboxidiene</span> Chemical compound

Herboxidiene is a polyketide molecule soluble in polar solvents such as water, ethanol, n-butanol and acetone but insoluble in non-polar molecule such as hexane. It was first isolated from the fermentation broth of Streptomyces chromofuscus by researchers in Monsanto Company in 1992. Herboxidiene shows in vitro antitumor activity by targeting the SF3B protein in the splicesosome. Many antitumor derivatives have also been developed from herboxidiene through chemical modification.

Fostriecin is a type I polyketide synthase (PKS) derived natural product, originally isolated from the soil bacterium Streptomyces pulveraceus. It belongs to a class of natural products which characteristically contain a phosphate ester, an α,β-unsaturated lactam and a conjugated linear diene or triene chain produced by Streptomyces. This class includes structurally related compounds cytostatin and phoslactomycin. Fostriecin is a known potent and selective inhibitor of protein serine/threonine phosphatases, as well as DNA topoisomerase II. Due to its activity against protein phosphatases PP2A and PP4 which play a vital role in cell growth, cell division, and signal transduction, fostriecin was looked into for its antitumor activity in vivo and showed in vitro activity against leukemia, lung cancer, breast cancer, and ovarian cancer. This activity is thought to be due to PP2A's assumed role in regulating apoptosis of cells by activating cytotoxic T-lymphocytes and natural killer cells involved in tumor surveillance, along with human immunodeficiency virus-1 (HIV-1) transcription and replication.

<span class="mw-page-title-main">Borrelidin</span> Chemical compound

Borrelidin is an 18-membered polyketide macrolide derived from several Streptomyces species. First discovered in 1949 from Streptomyces rochei, Borrelidin shows antibacterial activity by acting as an inhibitor of threonyl-tRNA synthetase and features a nitrile moiety, a unique functionality in natural products., Borrelidin also exhibits potent angiogenesis inhibition, which was shown in a rat aorta matrix model. Other studies have been performed to show that low concentrations of borrelidin can suppress growth and induce apoptosis in malignant acute lymphoblastic leukemia cells. Borredlidin's antimalarial activity has also been shown in vitro and in vivo.

<span class="mw-page-title-main">Annimycin</span> Polyenoic acid amide natural product produced by Streptomyces calvus

Annimycin (4-(Z)-annimycin) is a polyenoic acid amide natural product produced by Streptomyces calvus. Annimycin inhibits the sporulation of several actinobacterial genera.

Butyrolactol A is an organic chemical compound of interest for its potential use as an antifungal antibiotic.

Tylactone synthase or TYLS is a Type 1 polyketide synthase. TYLS is found in strains of Streptomyces fradiae and responsible for the synthesis of the macrolide ring, tylactone, the precursor of an antibiotic, tylosin. TYLS is composed of five large multi-functional proteins, TylGI-V. Each protein contains either one or two modules. Each module consists of a minimum of a Ketosynthase (KS), an Acyltransferase (AT), and an Acyl carrier protein (ACP) but may also contain a Ketoreductase (KR), Dehydrotase (DH), and Enoyl Reductase (ER) for additional reduction reactions. The domains of TYLS have similar activity domains to those found in other Type I polyketide synthase such as 6-Deoxyerythronolide B synthase (DEBS). The TYLS system also contains a loading module consisting of a ketosynthase‐like decarboxylase domain, an acyltransferase, and acyl carrier protein. The terminal Thioesterase terminates tylactone synthesis by cyclizing the macrolide ring. After the TYLS completes tylactone synthesis, the tylactone molecule is modified by oxidation at C-20 and C-23 and glycosylation of mycaminose, mycinose, and mycarose to produce tylosin.

<span class="mw-page-title-main">Phoslactomycin B</span> Chemical compound

Phoslactomycin (PLM) is a natural product from the isolation of Streptomyces species. This is an inhibitor of the protein serine/threonine phosphatase which is the protein phosphate 2A (PP2A). The PP2A involves the growth factor of the cell such as to induce the formation of mitogen-activated protein interaction and playing a role in cell division and signal transduction. Therefore, PLM is used for the drug that prevents the tumor, cancer, or bacteria. There are nowsaday has 7 kinds of different PLM from PLM A to PLM G which differ the post-synthesis from the biosynthesis of PLM.

<span class="mw-page-title-main">Aureothin</span> Chemical compound

Aureothin is a natural product of a cytotoxic shikimate-polyketide antibiotic with the molecular formula C22H23NO6. Aureothin is produced by the bacterium Streptomyces thioluteus that illustrates antitumor, antifungal, and insecticidal activities and the new aureothin derivatives can be antifungal and antiproliferative. In addition, aureothin, a nitro compound from Streptomyces thioluteus, was indicated to have pesticidal activity against the bean weevil by interfering with mitochondrial respiratory complex II.

<span class="mw-page-title-main">Prescopranone</span> Chemical compound

Prescopranone is a key intermediate in the biosynthesis of scopranones. Prescopranone is the precursor to scopranone A, scopranone B, and scopranone C, which are produced by Streptomyces sp. BYK-11038.

<span class="mw-page-title-main">Pladienolide B</span> Chemical compound

Pladienolide B is a natural product produced by bacterial strain, Streptomyces platensis MER-11107,which is a gram-positive bacteria isolated from soil in Japan. Pladienolide B is a molecule of interest due to its potential anti-cancer properties. Its anti-cancer mode of action includes binding to the SF3B complex in the U2 snRNP in the human spliceosome.

References

  1. Pham, Van Thuy Thi; Nguyen, Hue Thi; Nguyen, Chung Thanh; Choi, Ye Seul; Dhakal, Dipesh; Kim, Tae-Su; Jung, Hye Jin; Yamaguchi, Tokutaro; Sohng, Jae Kyung (2021-01-11). "Identification and enhancing production of a novel macrolide compound in engineered Streptomyces peucetius". RSC Advances. 11 (5): 3168–3173. doi:10.1039/D0RA06099B. ISSN   2046-2069.
  2. 1 2 3 4 Magar, Rubin Thapa; Pham, Van Thuy Thi; Poudel, Purna Bahadur; Nguyen, Hue Thi; Bridget, Adzemye Fovennso; Sohng, Jae Kyung (February 2023). "Biosynthetic pathway of peucemycin and identification of its derivative from Streptomyces peucetius". Applied Microbiology and Biotechnology. 107 (4): 1217–1231. doi:10.1007/s00253-023-12385-8. ISSN   1432-0614. PMID   36680588.
  3. Long, Paul F.; Wilkinson, Christopher J.; Bisang, Christian P.; Cortés, Jesús; Dunster, Nicholas; Oliynyk, Marko; McCormick, Ellen; McArthur, Hamish; Mendez, Carmen; Salas, José A.; Staunton, James; Leadlay, Peter F. (2002-03-22). "Engineering specificity of starter unit selection by the erythromycin-producing polyketide synthase: Engineered starter unit selection". Molecular Microbiology. 43 (5): 1215–1225. doi:10.1046/j.1365-2958.2002.02815.x.